Isomorphic Labs partners with Merck on AI-designed cancer drug
demishassabis · x · 2026-11-21
Demis Hassabis announced a strategic research collaboration between Isomorphic Labs and MSD (Merck) to design a new cancer drug, combining Isomorphic's frontier AI drug-design capabilities with Merck's discovery, development and manufacturing expertise.
Isomorphic's modality-agnostic drug design engine (IsoDDE) is built on foundational AI models offering high predictive fidelity in novel biological systems. Hassabis called it another key proof point of the company's push to reimagine drug discovery.
More from Companies & People
- WIRED reporter clarifies: firing was over 'lack of candor,' not national security probes — LaurenGoode · 2026-11-21
- Robotics supply chains can't be reshored — they still need to be built from scratch — theo_gervet · 2026-11-21
- WIRED: Jensen Huang's 'Lying' Alarmed Nvidia Board Ahead of His Resignation — Scobleizer · 2026-11-21
- Frontier agents complete under 8% of tasks in 26-person simulated org, study finds — vasuman · 2026-11-21
- Wired: Nvidia board alarmed by Jensen Huang's 'lack of candor' before resignation — Wired AI · 2026-11-21
- CMU's LTI celebrates 40 years with symposium honoring its NLP legacy — niloofar_mire · 2026-11-21